FAVORABLE BALANCE of BENEFIT and HARM of LONG-TERM, LOW-DOSE PREDNISOLONE ADDED to STANDARD TREATMENT in RHEUMATOID ARTHRITIS PATIENTS AGED 65+: The PRAGMATIC, MULTICENTER, PLACEBO-CONTROLLED GLORIA TRIAL
Annals of the Rheumatic Diseases
; 81:174-175, 2022.
Article
in English
| EMBASE | ID: covidwho-2008836
biological product; calcium; cyclic citrullinated peptide antibody; disease modifying antirheumatic drug; endogenous compound; glucocorticoid; placebo; prednisolone; aged; clinical trial; comorbidity; conference abstract; controlled study; coronavirus disease 2019; DAS28; double blind procedure; drug therapy; drug withdrawal; fatigue; female; follow up; human; joint destruction; low drug dose; major clinical study; multicenter study; outcome assessment; randomized controlled trial; rheumatoid arthritis; secondary analysis; X ray film
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS